Google DeepMind and AI for scientific research

The statement that stopped the Google I/O audience in their tracks

On May 20, 2026, during the Google I/O keynote, Demis Hassabis delivered a line destined to circulate for a long time. Google DeepMind's stated goal is to "reimagine the drug discovery process with the aim of one day curing all diseases." The delivery was completely impassive. Therefore, it wasn't the enthusiastic rhetoric typical of tech stages: it was a programmatic declaration.

In fact, as analyzed by The Verge in the Optimizer column , the technical context surrounding those words is anything but empty. Behind the statement lie three precise technological pillars: Gemini applied to scientific research, AlphaFold in its most advanced iteration, and the new AlphaGenome. So, it's worth breaking them down one by one.

AlphaFold, AlphaGenome, and Gemini: three layers of a single architecture

AlphaFold is already established history. In 2020 it solved one of the most complex problems in computational biology: predicting the three-dimensional structure of proteins starting from their amino acid sequence. Furthermore, by 2022 the public AlphaFold database had already cataloged over 200 million protein structures. As a result, the entire global scientific community has benefited directly.

AlphaGenome represents the next big step. Just like what was done with proteins, the model aims to crack the functional logic of the genome. Specifically, the goal is to figure out how genome changes mess with gene expression and, consequently, trigger diseases. It's a huge leap forward from just reading DNA sequences.

Gemini for science operates as a reasoning layer. However, it is not just a simple chatbot applied to biology. It's an engine capable of integrating heterogeneous data — scientific literature, genomic data, protein structures, clinical trials — and generating testable hypotheses. Thus, a research cycle that traditionally took years can be compressed into weeks.

The paradigm shift in drug discovery

The traditional drug discovery process is long, expensive, and has a high failure rate. According to McKinsey , taking a drug from the research phase to approval typically takes 10-15 years and over a billion dollars. Furthermore, the success rate of drug candidates in clinical phases remains below 10%.

AI applied to scientific research tackles this problem on multiple fronts at the same time. First of all, it speeds up the identification of molecular targets. Then, it optimizes the structure of candidate molecules even before physically synthesizing them. Finally, it can predict toxicity and adverse interactions with increasing accuracy. Therefore, the potential savings — in terms of time and resources — are structural, not marginal.

Despite this, real limitations remain. AI models reason on patterns within available data. Therefore, for rare diseases or poorly studied biological mechanisms, training data quality is a critical bottleneck. MIT Technology Review has documented just as AlphaFold shows significant margins of error on proteins with intrinsically disordered structures.

What does «curing all diseases» mean in practice

Hassabis's quote should be read as a strategic horizon, not a short-term promise. On the contrary, interpreting it literally would be an analytical error. However, it points in a precise direction: Google DeepMind is positioning itself as a global scientific infrastructure, not just a cloud service or productivity tool provider.

This positioning has major competitive implications. In fact, it sets Google DeepMind apart from OpenAI, Anthropic, and Microsoft on a completely different axis. While the main competition is fought on the battleground of general language models, DeepMind is dominating the scientific domain with specialized tools and proprietary datasets that are hard to copy. As a result, the competitive edge isn't just about computing power: it's epistemic.

Therefore, for anyone following the evolution of the AI market, Google I/O 2026 shifted the center of gravity of the conversation. People are no longer just talking about chatbots or text automation. They're talking about AI as the engine of scientific knowledge. At the same time, this opens up application scenarios that go beyond a single vertical sector.

The Google ecosystem and the race for vertical AI infrastructure

Google DeepMind doesn't work in isolation. On top of that, integration with Google Cloud, Gemini Pro models, and search APIs creates a seamless ecosystem. Pharmaceutical companies, universities, and research centers can jump right into these tools using setups they already know. That means getting started is a lot easier compared to closed, proprietary platforms.

Similarly, Google's strategy of making AlphaFold's databases public has built a powerful network advantage. Whoever uses the data implicitly contributes to its validation. Therefore, the business model is that of the enabling infrastructure: Google makes money on the processing, not on the knowledge itself. In short, it's an approach that reminds us of AWS with respect to cloud computing in its formative years.

For Italian SMEs operating in adjacent sectors — biotech, diagnostics, nutraceuticals, functional cosmetics — this ecosystem directly matters. AI solutions that we at SHM Studio build into our clients' business processes rely more and more on these infrastructure layers. So, keeping up with Google DeepMind's roadmap isn't just an academic exercise—it's smart strategic planning.

What nobody is saying: the gap between announcement and operational adoption

Tech keynotes tend to compress time. Between the announcement of a technology and its widespread operational adoption, there is always a gap. For this reason, it is useful to separate three distinct time horizons.

In the short term — 2026-2027 — Gemini's APIs for science will be accessible mainly to large organizations with internal technical capabilities. However, derived tools and simplified interfaces will gradually arrive for smaller players too. So, SMBs should keep an eye on things, not necessarily take action right away.

In the medium term — 2027-2028 — it is reasonable to expect the integration of scientific AI features into existing vertical SaaS platforms. For example, R&D management software, regulatory compliance platforms, or pharmaceutical market intelligence tools. Consequently, adoption will often happen indirectly, through updates to the tools already in use.

Over the long term, the impact will be structural across the entire research value chain. However, precisely quantifying the timeline and methods remains tricky. Even so, the direction is clear: AI is becoming an essential part of scientific research, not just an optional add-on.

Implications for Italian SMEs: where to look now

For Italian B2B companies that do not operate directly in biotech, the message of Google I/O 2026 is still indirectly relevant. In fact, the technological paradigms that Google DeepMind is consolidating in scientific research—multi-modal reasoning, integration of heterogeneous data, generation of verifiable hypotheses—are the same ones that will filter into marketing, SEO, and automation tools over the next 18-24 months.

In particular, SMEs should keep an eye on three key operational areas. First of all, the evolution of Google search engines: Gemini integrated into scientific research hints at features that will soon change commercial search too. Therefore, the strategies SEO must already today focus on high-information-density content and robust semantic structure.

Furthermore, the digital marketing tools will evolve towards deeper personalization, powered by AI models capable of reasoning on complex behavioral data. Therefore, investing now in clean and accessible data architectures is a priority. Finally, the web infrastructure must be ready to integrate next-generation AI APIs without requiring complete rebuilds.

From SHM Studio , the practical advice is not to wait for these technologies to be «ready for everyone» before starting to understand how they work. Instead, those who build a solid AI literacy today will be in an advantageous position when mass adoption arrives. To learn more about how to structure this transition, the team is available through the page contacts .

Outlook: where this trajectory leads

Google DeepMind has laid out an ambitious trajectory. However, the credibility of that trajectory is backed by concrete, already verifiable results: AlphaFold is a real tool, used by real researchers, with measurable impacts on research speed. Therefore, skepticism is legitimate, but it must not turn into analytical blindness.

In the next 24 months, Google DeepMind is likely to announce partnerships with top-tier pharmaceutical institutions and international regulatory agencies. Furthermore, competition with other players — particularly Microsoft's AI divisions and specialized startups like Recursion Pharmaceuticals — will heat up. As a result, the AI market for scientific research will become one of the most hotly contested spaces in the tech industry.

For those who follow the SHM Studio blog , this topic will return with regular updates. In short: Hassabis's statement at Google I/O 2026 is not an empty promise. It is the sign of a profound redefinition of AI's role in knowledge production. Understanding this redefinition is, today, a real competitive advantage. Also dive deeper into our thoughts on AI for businesses , SEO copywriting , google ads campaigns and LinkedIn campaigns to stay updated on the evolution of the digital landscape.